• Vaccine Name: Herpes simplex virus type 2 vaccine using phage displaying GG protein
• Target Pathogen: Herpes simplex virus type 1 and 2
• Target Disease: Herpes
• Vaccine Ontology ID: VO_0011420
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: Herpes simplex virus type 2 envelope glycoprotein G (US4)
• US4 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Phage clones were isolated that express peptides that mimic single epitopes of the glycoprotein G of HSV-2, gG2 (Grabowska et al., 2000).
  • Detailed Gene Information: Click Here.
• Immunization Route: Subcutaneous injection

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were obtained from a randomly bred, closed colony at the Sheffield University animal facility. Immunisations were administered subcutaneously at 2-week intervals. The dose given is the quantity of phage used per mouse per immunisation in a 200 ml volume of TBS. Prebleeds were obtained from a random selection of the mice prior to immunisation, and further bleeds were taken from all mice 2 weeks after each immunisation (Grabowska et al., 2000).
• Challenge Protocol: Four weeks after the last immunisation, mice were challenged with 5±6 mouse lethal doses of HSV-2 (strain 333). Survival of the mice was monitored daily (Grabowska et al., 2000).
• Efficacy: In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 (Grabowska et al., 2000).